Aromatase Deficiency Caused by a Novel P450arom Gene Mutation: Impact of Absent Estrogen Production on Serum Gonadotropin Concentration in a Boy
Abstract
We identified a new point mutation in the CYP19 gene responsible for aromatase (P450arom) deficiency in a 46,XY male infant with unremarkable clinical findings at birth. This boy is homozygote for a 1-bp (C) deletion in exon 5 of the aromatase gene causing a frame-shift mutation. The frame-shift results in a prematurely terminated protein that is inactive due to the absence of the functional regions of the enzyme. Aromatase deficiency was suspected prenatally because of the severe virilization of the mother during the early pregnancy, and the diagnosis was confirmed shortly after birth. Four weeks after birth, the baby boy showed extremely low levels of serum estrogens, but had a normal level of serum free testosterone; in comparison with the high serum concentration of androstenedione at birth, a striking decrease occurred by 4 weeks postnatally. We previously reported elevated basal and stimulated FSH levels in a female infant with aromatase deficiency in the first year of life. In contrast, in the male infant, basal FSH and peak FSH levels after standard GnRH stimulation tests were normal. This finding suggests that the contribution of estrogen to the hypothalamic-pituitary gonadotropin-gonadal feedback mechanism is different in boys and girls during infancy and early childhood. In normal girls, serum estradiol concentrations strongly correlate with circulating inhibin levels, and thus, low inhibin levels may contribute to the striking elevation of FSH in young girls with aromatase deficiency. In contrast, estradiol levels are physiologically about a 7-fold lower in boys than in girls, and serum inhibin levels remain elevated even though levels of FSH, LH, and testosterone are decreased.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
All adult aromatase-deficient men have unfused epiphyses leading to linear growth into adulthood and above-average body length.
“All adult aromatase-deficient men demonstrated a remarkably low bone mass and unfused epiphyses leading to linear growth into adulthood and above-average body length.”
From Aromatase inhibitors in men: effects and therapeutic options (2011) · cites this paper as [19]
Once treated with estradiol, epiphyses closed in most aromatase-deficient men.
“Once treated with estradiol, epiphyses closed, BMD increased and disturbances in the lipid profile improved in most of these patients.”
From Aromatase inhibitors in men: effects and therapeutic options (2011) · cites this paper as [19]
All adult aromatase-deficient men demonstrated a remarkably low bone mass.
“All adult aromatase-deficient men demonstrated a remarkably low bone mass and unfused epiphyses leading to linear growth into adulthood and above-average body length.”
From Aromatase inhibitors in men: effects and therapeutic options (2011) · cites this paper as [19]
Once treated with estradiol, BMD increased in most aromatase-deficient men.
“Once treated with estradiol, epiphyses closed, BMD increased and disturbances in the lipid profile improved in most of these patients.”
From Aromatase inhibitors in men: effects and therapeutic options (2011) · cites this paper as [19]
Once treated with estradiol, disturbances in the lipid profile improved in most aromatase-deficient men.
“Once treated with estradiol, epiphyses closed, BMD increased and disturbances in the lipid profile improved in most of these patients.”
From Aromatase inhibitors in men: effects and therapeutic options (2011) · cites this paper as [19]
Cited by
Sorted by citations
Of mice and men: the evolving phenotype of aromatase deficiency
Jones, M. E. E., Chin Boon, W., Proietto, J., & Simpson, E. R. (2006) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2006.01.004 · Cited by 193 · see citing works
Aromatase inhibitors in men: effects and therapeutic options
de Ronde, W., & de Jong, F. H. (2011) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-9-93 · Cited by 155 · see citing works
Effect of estrogen deficiency in the male: the ArKO mouse model
Murata, Y., Robertson, K. M., Jones, M. E. E., & Simpson, E. R. (2002) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(02)00090-4 · Cited by 111 · see citing works
The Aromatase Cytochrome P-450 and Its Clinical Impact
Meinhardt, U., & Mullis, P.-E. (2002) · Hormone Research in Paediatrics · doi:10.1159/000058374 · Cited by 68 · see citing works
Therapeutic uses of aromatase inhibitors in men
de Ronde, W. (2007) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e328121aad2 · Cited by 26 · see citing works
- Authors
- Deladoey, J.
- Venue
- Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1999-11-01
- Volume
- 84
- Issue
- 11
- Pages
- 4050-4054
- ISSN
- 0021-972X (ISSN-L)
- OpenAlex
- W4245919277
- Cited by
- 70
- References
- 0
- Citations by year
- 2023: 2 · 2022: 1 · 2020: 2 · 2019: 5 · 2018: 1 · 2017: 2 · 2016: 2 · 2015: 1 · 2014: 2 · 2013: 3 · 2012: 2
- FWCI
- 1.14
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- Bern Open Repository and Information System (University of Bern) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Sexual Differentiation and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities
- Health Sciences › Medicine › Reproductive Medicine › Hypothalamic control of reproductive hormones
- Keywords
- aromatase deficiency, aromatase, P450arom, frameshift mutation, 46,XY disorders of sex development, male infants, serum gonadotropins, follicle-stimulating hormone, GnRH stimulation test, androstenedione, estradiol, inhibin, congenital adrenal hyperplasia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review